LANCORA® - A new add-on treatment for heart failure with elevated heart rate

Drug Review: Volume 17, Issue 6 - Download PDF

Heart failure is a condition where the heart has trouble pumping blood to keep up with the needs of the body’s organs and tissues. Common symptoms of heart failure include difficulty breathing, fatigue, and fluid retention.

400,000 Canadians suffer from heart failure and it is the leading cause of hospitalization for the elderly in Canada. Heart failure is responsible for 9% of all deaths in Canada.

The current treatment guidelines focus on improving patient symptoms and preventing disease progression. Patients will be prescribed an Angiotensin-converting-enzyme inhibitor (ACE inhibitor) or Angiotensin II receptor blockers (ARBs) along with a beta-blocker to protect the heart. Diuretics (water pills) could be prescribed to help reduce fluid retention. These standard therapies each cost $200/year or less.

Even when beta-blocker therapy is optimized, patients may still have an elevated heart rate. An elevated heart rate is a known risk factor for both increased mortality and hospital re-admission in heart failure patients.

Patients who are experiencing a high heart rate, while adhering to a traditional treatment plan may benefit from LANCORA®. Lancora® reduces the heart rate by increasing the length of time between beats. Clinical studies have shown that adding LANCORA® to a standard treatment plan can prolong life and reduce hospitalization.

 LANCORA® is available as a tablet containing either 5mg or 7.5mg of ivabradine. The standard dose ranges from 5mg to 7.5mg twice daily. The annual cost of therapy ranges from $650 to $1,100.


Drug Name


Drug Ingredients


Annual Cost

$650 - $1100

Coverage Details

Special Authorization for Managed Formularies.

Fully covered for Open Formularies.